NCT00395434已完成1 期
OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors
Mateon Therapeutics4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2006年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- safety and tolerability of the combination therapy assessed by analysis of adverse events
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be defined if it is at one of the three dose levels under study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histopathologically or cytologically confirmed malignant solid tumors that have failed standard therapy or for which no life prolonging treatment exists
- •Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria
- •At least 4 weeks since any prior immunotherapy, chemotherapy or radiation therapy prior to first dose of study drug (six weeks for therapy known to be associated with delayed toxicity such as nitrosoureas or mitomycin-C)
- •Age > or = to 18 years old
- •Adequate bone marrow function:
- •absolute granulocyte count (neutrophils and bands) > or = to 1500 cells/mm3;
- •platelet count > or = to 100,000 cells/mm3;
- •hemoglobin > or = to 9 g/dL.
- •Adequate renal function (glomerular filtration calculated by Cockcroft/Gault formula or measure urine creatinine clearance > or = to 50 mL/minute)
- •Adequate hepatic function:
- •bilirubin less than or = to 1.5 mg/dL;
- •aspartate transaminase (AST) and alanine transaminase (ALT) less than or = to 2.5 times the institutional upper limit of normal (ULN) (or less than or = to 5 times ULN if liver metastases are present).
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Life expectancy of > or = to 12 weeks
- •Written, signed, dated, and witnessed (if applicable as per International Conference on Harmonization [ICH] guidelines) Independent Ethics Committee (IEC) approved informed consent form before any study specific screening procedures are performed
- •Fertile subjects must abstain from sexual intercourse or use effective birth control.
- •All women of child bearing potential (WOCBP) must have a negative serum pregnancy test within 72 hours of first dose.
排除标准
- •Contraindications, allergies or sensitivity to the use of the study medications or any other products required for participation in this study (i.e. contrast agents)
- •Presence of central nervous system (CNS) metastases
- •Diagnosed squamous non-small cell lung cancer (NSCLC)
- •History of gastrointestinal perforations
- •Surgery within 28 days of screening visit or a surgical incision that is not fully healed. Any surgery planned during the study period.
- •Proteinuria >1 g/24 hours by 24 hour urine collection (perform 24 hour urine collection if > 1+ on dipstick)
- •Recent hemoptysis (occurrence within the past 3 months)
- •Prior therapy with CA4P or bevacizumab, or other agents which target vascular endothelial growth factor (VEGF) or VEGFR signaling such as Sorafenib and Sutent
- •Prior radiation involving > 30% of the bone marrow
- •Radical radiotherapy to the thorax or abdomen at any time or post-operative radical radiotherapy to the pelvis. Palliative radiotherapy treatments are acceptable. Subjects with rectal primaries who have received pre-operative pelvic radiotherapy or chemoradiation are eligible if the small bowel was mobile and not stuck to the tumor.
- •Active autoimmune disorder(s)
- •Immunocompromised, including subjects known to be human immunodeficiency virus (HIV) positive
- •Active infection requiring antibiotic therapy or any other serious intercurrent illness
- •History of angina (stable or severe, even if controlled with medications), myocardial infarction, congestive heart failure (CHF), non-controlled atrial arrhythmias or clinically significant arrhythmias including conduction abnormality, nodal junctional arrhythmias and dysrhythmias, sinus bradycardia or tachycardia, supraventricular arrhythmias, atrial fibrillation or flutter, syncope or vasovagal episodes
- •Electrocardiogram (ECG) with evidence of prior myocardial infarction (e.g., significant Q waves), QTc > 450 msec or other clinically significant abnormalities
- •Taking any drug(s) known to prolong the QTc interval, which cannot be interrupted for at least four days during each treatment cycle.
- •Known significant heart wall abnormality or heart muscle damage as evidenced on multiple-gated acquisition (MUGA) scan or echocardiogram (this is not a required screening investigation)
- •Uncontrolled hypertension (defined as blood pressure consistently greater than 150/100 irrespective of medication). Or controlled hypertension requiring use of > 2 classes of anti-hypertensives.
- •Uncontrolled hypokalemia and/or hypomagnesemia
- •Symptomatic peripheral vascular disease or cerebrovascular disease
- •Psychiatric disorders or other conditions rendering subjects incapable of complying with the requirements of the protocol
- •Receiving concurrent hormonal therapy with the exception of gonadotropin-releasing hormone (GnRH) agonists in subjects with hormone refractory prostate cancer, hormone replacement therapy (HRT), oral contraceptives, and megestrol acetate used for anorexia/cachexia
- •Receiving anticoagulation with warfarin, heparin or low molecular weight heparin other than low dose (1 mg) warfarin for maintenance of central line patency
- •Women who are currently pregnant, nursing, or planning a pregnancy; or women who have a positive pregnancy test.
- •Receiving concurrent antineoplastic therapy (radiation therapy, cytotoxic or biologic therapy)
- •Participation in an investigational drug or device trial within 30 days of entering the study.
结局指标
主要结局
safety and tolerability of the combination therapy assessed by analysis of adverse events
safety and tolerability of the combination therapy assessed by analysis of laboratory tests
safety and tolerability of the combination therapy assessed by analysis of other assessments within the protocol
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)HIVHIV InfectionsNCT00850616Merck Sharp & Dohme LLC147
已完成
1 期
Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male SubjectsHealthyNCT00619736Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsAlzheimer DiseaseHealthyNCT00684710Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
99mTc-rhAnnexin V-128: a First In Man Study in Healthy VolunteersHealthy Adult VolunteersNCT02182609Advanced Accelerator Applications14
已完成
1 期
Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202Parkinson's DiseaseNCT02763787Bial - Portela C S.A.71